Skip to main content

Understanding the effects of cyclo-oxygenase inhibition in the zebrafish

Millions of people worldwide use non-steroidal anti-inflammatory drugs (NSAIDs) to treat a wide variety of health conditions involving inflammation and pain In addition to their positive therapeutic effect, the use of NSAIDs, especially when long-term, is associated with an increased risk of adverse events in multiple organs/systems, including gastrointestinal and cardiovascular systems.

These pharmaceuticals act by inhibiting one or both isoforms of the enzyme cyclo-oxygenase (COX), which catalyse the synthesis of prostaglandins, chemicals that promote inflammation, pain, and fever. Major advances have been made in our understanding of NSAIDs pharmacology and toxicology; however, many aspects of the biological significance of COX inhibition still remain poorly understood. In this project, we will use the zebrafish as the experimental model to study the effects of NSAIDs on the immune and gastro-intestinal systems and will explore the interplay between the two responses.


Meet the Principal Investigator(s) for the project

Dr Luigi Margiotta-Casaluci

Related Research Group(s)

human body

Inflammation Research and Translational Medicine - Driving scientific innovation and discovery for diagnosis, treatment, and management of cardiovascular disease, inflammatory and immune disorders, microbial resistance, and cancer.


Partnering with confidence

Organisations interested in our research can partner with us with confidence backed by an external and independent benchmark: The Knowledge Exchange Framework. Read more.


Project last modified 12/01/2024